Vascular normalization: A real benefit?

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 2, 2011, Pages 275-278

  Ribatti, Domenico ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

Angiogenesis; Antiangiogenesis; Chemotherapy; Vascular normalization; VEGF

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; AZ 2171; BEVACIZUMAB; CEDIRANIB; COLLAGEN TYPE 4; HYPOXIA INDUCIBLE FACTOR 1; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; BLOOD BRAIN BARRIER; BLOOD VESSEL PERMEABILITY; CANCER INVASION; CANCER SURVIVAL; ENDOTHELIUM CELL; GLIOBLASTOMA; HUMAN; HYPOXIA; MELANOMA; METASTASIS; NONHUMAN; OVERALL SURVIVAL; PERICYTE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; TISSUE PRESSURE; TUMOR VASCULARIZATION; VASCULAR NORMALIZATION;

ANGIOGENESIS INHIBITORS; ANGIOPOIETINS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PERICYTES; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 79960924361     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1683-z     Document Type: Review

References (41)

1. EK Marchall Jr 1964 Historical perspectives in chemotherapy Adv Chemother 13 1 8
2. J Folkman 1971 Tumor angiogenesis: therapeutic implications N Engl J Med 285 1182 1186 4938153 10.1056/NEJM197108122850711 1:STN:280: DyaE38%2FgvVCqsQ%3D%3D
3. F Hurwitz L Fehrenbacher W Novotny, et al. 2004 Bevacizumab plus irinotecan, and leucovurin for metastatic colorectal cancer N Engl J Med 350 2335 2342 15175435 10.1056/NEJMoa032691 1:CAS:528:DC%2BD2cXks1Gjt74%3D (Pubitemid 38702844)
4. K Miller M Wang J Gralow, et al. 2007 Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2666 2676 18160686 10.1056/NEJMoa072113 1:CAS:528:DC%2BD1cXisVOnsg%3D%3D
5. A Sandler R Gray MC Perry, et al. 2006 Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2542 2550 17167137 10.1056/NEJMoa061884 1:CAS:528:DC%2BD28XhtlWqsbzI (Pubitemid 44917502)
6. G Goss A Arnold F Shepherd, et al. 2010 Randomized, double-blind trial of carboplatin and paclitaxel with either oral cediranib or placebo in advanced non-small cell lung cancer. NCIC clinical trial group BR24 study J Clin Oncol 28 49 55 19917841 10.1200/JCO.2009.22.9427 1:CAS:528:DC%2BC3cXhtF2ku7Y%3D
7. Herbst R, Sun Y, Korfee S et al (2009) Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZODIAC). J Clin Oncol, vol 27, Abstr CRA8003
8. De Boer R, Arrieta O, Gottbried M et al (2009) Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZEAL). J Clin Oncol, vol 27, Abstr 8010
9. K Inoue M Chikazawa S Fukata C Yoshikawa T Shuin 2003 Docetaxel enhances the therapeutic effect of the angiogenesis inhibitor TNP-470 (AGM-1470) in metastatic human transitional cell carcinoma Clin Cancer Res 9 886 899 12576464 1:CAS:528:DC%2BD3sXhtVKktrk%3D (Pubitemid 36182629)
10. S Song MG Wientijes C Walssh JL Au 2001 Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases Cancer Res 61 6145 6150 11507065 1:CAS:528:DC%2BD3MXmt12ktLc%3D (Pubitemid 32762551)
11. D Ribatti B Nico E Crivellato A Vacca 2007 The structure of the vascular network of tumors Cancer Lett 248 18 23 16879908 10.1016/j.canlet.2006.06.007 1:CAS:528:DC%2BD2sXisVWlsr4%3D
12. HF Dvorak JA Nagy JT Dvorak AM Dvorak 1988 Identification and characterization of the blood vessel of solid tumors that are leaky to circulating macromolecules Am J Pathol 133 95 109 2459969 1:STN:280: DyaL1M%2FitlCksQ%3D%3D
13. D Daldrup DM Shames M Wendland Y Okuhata TM Link W Rosenau, et al. 1998 Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media Am J Roentgenol 171 941 949 1:STN:280:DyaK1cvjtl2gtQ%3D%3D (Pubitemid 28449949)
14. DM Mc Donald PL Choyke 2003 Imaging of angiogenesis: from microscope to clinic Nat Med 9 713 725 10.1038/nm0603-713 1:CAS:528:DC%2BD3sXktFOnurs%3D (Pubitemid 36749220)
15. DR Senger L Brown K Claffey A Dvoark 1995 Vascular permeability factor, tumor angiogenesis and stroma generation Invasion Metastasis 14 385 394 1:STN:280:DyaK2Mzos1ertw%3D%3D
16. HK Dvorak VS Harvey P Estrella LF Brown J Mc Donagh AM Dvorak 1987 Fibrin containing gels induce angiogenesis: implications for tumor stroma generation and wound healing Lab Invest 57 673 686 2447383 1:CAS:528:DyaL1cXht12nsL0%3D (Pubitemid 18031786)
17. D Fukumura T Sjoblom A Abramsson J Ellingsen P Micke H Li, et al. 1998 Tumor induction of VEGF promoter activity in stromal cells Cell 94 715 725 9753319 10.1016/S0092-8674(00)81731-6 1:CAS:528:DyaK1cXmtlCjs7o%3D (Pubitemid 28436004)
18. D Ribatti B Nico E Crivellato AM Roccaro A Vacca 2007 The history of the angiogenic switch concept Leukemia 21 44 52 16990761 10.1038/sj.leu.2404402 1:CAS:528:DC%2BD28XhtlSqurzI (Pubitemid 44921833)
19. RK Jain 2001 Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy Nat Med 7 987 989 11533692 10.1038/nm0901-987 1:CAS:528:DC%2BD3MXmvFOmsrc%3D (Pubitemid 32937367)
20. D Fukumura DG Duda LL Munn RK Jain 2010 Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models Microcirculation 17 206 225 20374484 10.1111/j.1549-8719.2010.00029.x 1:CAS:528:DC%2BC3cXlslWrtrs%3D
21. RT Tong Y Boucher SV Kozin F Winkler DJ Hicklin RK Jain 2004 Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors Cancer Res 64 3731 3736 15172975 10.1158/0008-5472.CAN-04-0074 1:CAS:528:DC%2BD2cXksVKgur8%3D (Pubitemid 38697278)
22. RK Jain 2005 Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 307 58 62 15637262 10.1126/science.1104819 1:CAS:528:DC%2BD2MXnvFar (Pubitemid 40093472)
23. F Winkler SV Kozin RT Tong SS Chae MF Booth I Garkavstev, et al. 2004 Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1 and matrix metalloproteinases Cancer Cell 6 553 563 15607960 1:CAS:528: DC%2BD2MXktVantw%3D%3D (Pubitemid 40017699)
24. P Baluk S Morikawa A Haskell M Mancuso DM Mc Donald 2003 Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors Am J Pathol 163 1801 1815 14578181 10.1016/S0002-9440(10)63540-7 (Pubitemid 37310012)
25. Sato Y (2011) Persistent vascular normalization as an alternative goal of anti-angiogenic cancer therapy. Cancer Sci. doi: 10.1111/j.1349-7006.2011. 01929.x. [Epub ahead of print]
26. GL Semenza 2003 Targeting HIF-1 for cancer therapy Nat Rev Cancer 3 721 732 13130303 10.1038/nrc1187 1:CAS:528:DC%2BD3sXotFCiu70%3D (Pubitemid 37328811)
27. M Paez-Ribes A Allen J Hudock T Takeda H Okuyama F Vinals, et al. 2009 Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis Cancer Cell 15 222 231 10.1016/j.ccr.2009.01.027
28. S Morikawa P Baluk T Kaidoh A Haskell RK Jain DM Mc Donald 2002 Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors Am J Pathol 160 985 1000 11891196 10.1016/S0002-9440(10)64920-6 (Pubitemid 34224587)
29. Ribatti D, Nico B, Crivellato E (2011) The role of pericytes in angiogenesis. Int J Dev Biol. doi: 10.1387/ijdb.103167dr
30. G Bergers S Song N Meyer-Morse E Bergland D Hanahan 2003 Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors J Clin Invest 111 1287 1295 12727920 1:CAS:528: DC%2BD3sXjsFCrsr4%3D (Pubitemid 36554699)
31. T Inai M Mancuso H Hashizume F Baffert A Haskell P Baluk, et al. 2004 Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts Am J Pathol 165 35 52 15215160 10.1016/S0002-9440(10)63273-7 1:CAS:528:DC%2BD2cXmtFygsrc%3D (Pubitemid 38821812)
32. CG Willett Y Boucher E di Tomaso DG Duda LL Munn RT Tong, et al. 2004 Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat Med 10 145 147 14745444 10.1038/nm988 1:CAS:528:DC%2BD2cXoslKmtQ%3D%3D (Pubitemid 38524883)
33. I Helfrich I Scheffrahn S Bartling J Weis V von Felbert M Middleton, et al. 2010 Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma J Exp Med 207 491 503 20194633 10.1084/jem.20091846 1:CAS:528:DC%2BC3cXjvVOhsL0%3D
34. AD Norden J Drappatz PY Wen 2009 Antiangiogenic therapies for high-grade glioma Nat Rev Neurol 5 610 620 19826401 10.1038/nrneurol.2009.159 1:CAS:528:DC%2BD1MXhtlKhtLbE
35. V Martin D Liu C Gomez-Manzano 2009 Encountering and advancing through antiangiogenic therapy for gliomas Curr Pharm Des 15 353 364 19199963 10.2174/138161209787315819 1:CAS:528:DC%2BD1MXjvVOnu78%3D
36. TT Batchelor AG Sorensen E di Tomaso Wt Zhang DG Duda KS Cohen, et al. 2007 AZD2171, a pan VEGF receptor tyrosine kinase inhibitor normalizes tumor vasculature and alleviates edema in glioblastoma patients Cancer Cell 11 83 95 17222792 10.1016/j.ccr.2006.11.021 1:CAS:528:DC%2BD2sXhtFClsLc%3D (Pubitemid 46075199)
37. TT Batchelor DG Duda E di Tomaso M Ancukiewicz SR Plotkin E Gerstner, et al. 2010 Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma J Clin Oncol 28 2817 2823 20458050 10.1200/JCO.2009.26.3988 1:CAS:528:DC%2BC3cXptFKmu78%3D
38. AG Sorensen TC Batchelor WT Zhang PJ Chen P Yeo M Wang, et al. 2009 A "vascular normalization index" as a potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients Cancer Res 69 5296 5300 19549889 10.1158/0008-5472.CAN-09-0814 1:CAS:528:DC%2BD1MXnvFWqurY%3D
39. MC McGee JB Hammer RF Willimas SF Rosati TL Sims CY Ng, et al. 2010 Improved intratumoral oxygenation through vascular normalization increases glioma sensitivity to ionizing radiation Int J Radiat Oncol Biol Phys 76 1537 1545 20338480 10.1016/j.ijrobp.2009.12.010 1:CAS:528:DC%2BC3cXjvFCksLw%3D
40. M Sie M Wagemakers G Molem JJ Mooij ES de Bont WF den Dunner 2009 The angiopoietin-1/angiopoietin-2 balance as a prognostic marker in primary glioblastoma multiforme J Neurosurg 110 147 155 18991494 10.3171/2008.6.17612
41. SS Chae WS Kamoun CT Farrar, et al. 2010 Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas Clin Cancer Res 16 3618 3627 20501615 10.1158/1078-0432.CCR-09-3073 1:CAS:528:DC%2BC3cXovVansbg%3D